Centrus signs HALEU supply agreement with Radiant for microreactors, adding another customer and prepayments

What happened

Centrus announced a definitive multi-year contract to supply HALEU to Radiant for its Kaleidos microreactors, adding another non-DOE customer and including prepayments to support capacity buildout. This complements Centrus' existing DOE-funded HALEU operations and backlog, but the scale of Radiant's near-term demand is likely small given the early stage of microreactor deployment. The prepayments provide some non-dilutive funding, but they are unlikely to match the $900M DOE task order that remains non-definitive and is the primary value driver. The agreement does not resolve the key near-term risk of DOE funding continuity beyond June 30, 2026, as highlighted in the latest 10-Q. While positive for demand diversification, it does not alter the need for definitive DOE milestones to support current valuation.

Implication

Investors should view this as modestly positive but not a de-risking event; Radiant's microreactor timeline is unproven and volume likely small initially. The prepayments help balance sheet and show private-sector interest, but they are likely a fraction of the capex needed. The master report's WAIT rating and $185 base case remain appropriate; the stock already prices a funded DOE path. Watch for further clarity on contract size, delivery schedule, and Radiant's funding and regulatory progress. Near-term focus remains on DOE definitive agreement and operating extension; this news alone does not justify a rating change.

Thesis delta

Thesis unchanged: this agreement adds a second HALEU customer and prepayments, providing incremental support for demand and cash, but the primary underwriting variable remains the $900M DOE task order definitization and operating continuity beyond June 2026. No change to WAIT rating or valuation scenarios; this is a minor positive but not sufficient to alter risk/reward.